Literature DB >> 8667193

Buprenorphine differentially alters opioid receptor adaptation in rat brain regions.

M M Belcheva1, M T Ho, E G Ignatova, L B Jefcoat, J Barg, Z Vogel, R J McHale, F E Johnson, C J Coscia.   

Abstract

Previous in vivo studies revealed that the mixed agonist-antagonist buprenorphine can down-regulate mu and up-regulate delta 2 and kappa 1 opioid receptors in rat brain. In this report brain regional differences in opioid receptor adaptation were addressed. Rats received i.p. injections with buprenorphine (0.5-2.5 mg/kg) and were killed 20 h later. Membranes from 7 brain regions were analyzed for mu (3H-[D-Ala2,N-mephe4,Gly-ol5] enkephalin), kappa 1 (3H-U-69593), delta 1 (3H-[D-Pen2, D-Pen5] enkephalin) and delta 2 (3H-deltorphin II) receptor binding parameters. Buprenorphine induced down-regulation of mu receptors in frontal cortex, occipital cortex, thalamus, hippocampus, striatum and brain stem. Kd values for 3H-[D-Ala2,N-mephe4,Gly-ol5] enkephalin were unchanged from controls. Up-regulation of kappa 1 receptors was observed in frontal, parietal, occipital cortexes and striatum. Binding to delta 2 sites was elevated in frontal and parietal cortexes. Buprenorphine did not alter delta 1 binding in any of the regions examined. Changes in opioid receptor adaptation induced by buprenorphine were further supported by data from cross-linking of 125I-beta-endorphin to cortical membrane preparations. A reduction in a 60- to 65-kDa band was detected in frontal and occipital cortices in which binding assays revealed down-regulation of mu receptors. In parietal cortex neither the 60- to 65-kDa product nor Bmax changes were observed. These results indicate that buprenorphine is a useful tool to study brain opioid receptor adaptation in vivo and the information accrued may be relevant to the mode of action of this drug in the treatment of heroin and cocaine abuse.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667193      PMCID: PMC1805810     

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  46 in total

1.  Characterization of beta-125I-endorphin cross-linked proteins in NG108-15 cell membranes. A 25-kilodalton protein with properties of delta-opioid-binding site.

Authors:  J L Ko; N M Lee; H H Loh
Journal:  J Biol Chem       Date:  1992-06-25       Impact factor: 5.157

2.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

Review 3.  Role of receptor regulation in opioid tolerance mechanisms.

Authors:  H H Loh; P L Tao; A P Smith
Journal:  Synapse       Date:  1988       Impact factor: 2.562

4.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

5.  Down-regulation of delta but not mu opioid receptors in the hippocampal slice associated with loss of physiological response.

Authors:  R Dingledine; R J Valentino; E Bostock; M E King; K J Chang
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

6.  Cross-linking of [125I]beta-endorphin to mu-opioid receptors during development.

Authors:  S McLean; R B Rothman; D M Chuang; K C Rice; J W Spain; C J Coscia; B L Roth
Journal:  Brain Res Dev Brain Res       Date:  1989-02-01

7.  Selective changes in mu opioid receptor properties induced by chronic morphine exposure.

Authors:  L L Werling; P N McMahon; B M Cox
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Purification to homogeneity of an active opioid receptor from rat brain by affinity chromatography.

Authors:  S Loukas; M Mercouris; F Panetsos; C Zioudrou
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions.

Authors:  J E Dum; A Herz
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

10.  Covalent labeling of opioid receptors with radioiodinated human beta-endorphin. Identification of binding site subunit.

Authors:  A D Howard; S de La Baume; T L Gioannini; J M Hiller; E J Simon
Journal:  J Biol Chem       Date:  1985-09-05       Impact factor: 5.157

View more
  3 in total

1.  Evidence for kappa- and mu-opioid receptor expression in C6 glioma cells.

Authors:  L M Bohn; M M Belcheva; C J Coscia
Journal:  J Neurochem       Date:  1998-05       Impact factor: 5.372

Review 2.  Effects of Taijiquan and Qigong exercises on depression and anxiety levels in patients with substance use disorders: A systematic review and meta-analysis.

Authors:  Peng Zhang; Zaimin Li; Qing Yang; Jiali Zhou; Xiujie Ma
Journal:  Sports Med Health Sci       Date:  2021-12-30

3.  Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.

Authors:  T-K Clarke; R C Crist; A Ang; L M Ambrose-Lanci; F W Lohoff; A J Saxon; W Ling; M P Hillhouse; R D Bruce; G Woody; W H Berrettini
Journal:  Pharmacogenomics J       Date:  2013-10-15       Impact factor: 3.550

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.